Tomorrows Medicines, a UK firm that offers an Internet solution to recruit and retain global participants for clinical trials has secured funding of more than £250,000 from a group of investors.
The Daresbury Sci-Tech, Cheshire-based firm has secured £100,500 from The North West Fund for Biomedical, managed by SPARK Impact, another £100,500 from private investors and £50,000 from the Technology Strategy Board.
Tomorrows Medicines has developed an interactive web platform, called YourTreatmentChoices.com, where patients can find and join local clinical trials. It also services global pharmaceutical, biotech, diagnostic, academic and other research organisation study teams in recruiting and retaining trial participants.
The funding will be used to commercialise the YourTreatmentChoices.com platform and service. So far, the website has helped patients in 78 countries to find approved clinical trials in their local area.
‘We are delighted to receive the funding from the three parties and to receive recognition that the company provides an important service offering,’ said Dr Clare Nolan, CEO of Tomorrows Medicines.
‘It will enable us to provide a fully-supported service to global pharmaceutical, biotech and diagnostic companies looking to accelerate patient recruitment across all clinical areas. The clinical trial recruitment process is critical for the discovery of much-needed medical treatments and we can now make this process simpler, faster and more accessible.’
